Comparing Wegovy, Ozempic, Mounjaro, Rybelsus, And Zepbound: Which Is Right For You?
Semaglutide (Wegovy, Ozempic, and Rybelsus) and Tirzepatide (Zepbound and Mounjaro) are two types of medications sold under several brand names. We compare their costs, effectiveness, administration methods, and side effects to help you understand which may be most suitable for your needs.
Injectable drugs are becoming increasingly popular for weight loss. For those who have not had success losing weight with diet and exercise alone, or who have additional health concerns including type 2 diabetes or high blood pressure, medications like Wegovy, Zepbound, Mounjaro, Rybelsus, or Ozempic can make a significant difference.
For people who are obese or overweight, losing 5-10% of total body weight can significantly improve health and reduce the risk of additional concerns like cardiovascular disease. And research has shown that injectable medications lead to an average weight loss of 8-15% within the first year to year and a half.
But with a growing number of choices available, how can you make an informed decision about which option might be right for you? Here, we’ll explore and compare the differences and similarities between each of these drugs, including how they work, what they cost, which conditions they’re approved for, how to take them, possible side effects, and more.
Get At-Home Medical Weight Loss Therapy
Lose weight with semaglutide weight loss injections (the same ingredient in Wegovy & Ozempic). If you are eligible, in-home medical weight loss treatments may help you reach your health goals.
ORDER NOWMedical Weight Loss Medications
Wegovy, Ozempic, Mounjaro, Rybelsus, and Zepbound are all similar in a number of ways, but there are also some key differences between them.
Each of these five medications is a brand name for one of two active ingredients: tirzepatide or semaglutide.
All of these drugs work by mimicking one to two specific hormones that the body makes naturally, and which help with blood sugar management and appetite control.
These hormones are called glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). They’re both made by the small intestine after you eat, and they send signals to the body to release more insulin and produce less glucose. They also slow down the passage of food through the digestive tract, and send signals to the brain to reduce appetite and feelings of hunger.
Medications that mimic GLP-1 and/or GIP (known as GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists) were originally developed to help treat type 2 diabetes. However, when researchers and patients observed weight loss benefits in addition to improvements in blood sugar, new versions of the medications were developed specifically to target obesity and weight concerns.
While all of the medications being compared can help with weight loss, some are FDA approved for obesity and overweight, and others are approved for type 2 diabetes.
A few things to consider when comparing and choosing between different injectable (and non-injectable) weight loss drugs include treatment success, your condition and health goals, cost and insurance coverage, availability, and delivery method.
It’s important to discuss your options with your healthcare provider, as they may have a more specific and personalized recommendation for you based on your current weight, health history, and condition.
Before we get into the details, here is a quick overview of the basic differences between these popular weight loss drugs:
| Drug | Active ingredient | Drug class | FDA approved for | Format | Est. monthly cost in USD |
|---|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 agonist | Weight loss in some groups | Injectable | $1349 |
| Ozempic | Semaglutide | GLP-1 agonist | Type 2 diabetes, CV disease risk reduction in some groups | Injectable | $968 |
| Mounjaro | Tirzepatide | Dual GIP/GLP-1 agonist | Type 2 diabetes | Injectable | $1069 |
| Rybelsus | Semaglutide | GLP-1 agonist | Type 2 diabetes | Oral pill | $969 |
| Zepbound | Tirzepatide | Dual GIP/GLP-1 agonist | Weight loss in some groups | Injectable | $1060 |
Get At-Home Medical Weight Loss Therapy
Lose weight with semaglutide weight loss injections (the same ingredient in Wegovy & Ozempic). If you are eligible, in-home medical weight loss treatments may help you reach your health goals.
ORDER NOWTirzepatide vs Semaglutide
Both tirzepatide (the active ingredient in Mounjardo and Zepbound) and semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) works as GLP-1 receptor agonists, which means that they mimic the hormone GLP-1.
However, tirzepatide also mimics a second hormone, GIP. This makes it a dual GLP-1/GIP receptor agonist. Both GLP-1 and GIP help to signal the body to produce more insulin and lower blood sugar, and both can help to keep you feeling full for longer. But GIP may enhance the effects of GLP-1.
Tirzepatide and semaglutide have both been shown to be effective for weight loss, blood sugar control, and cardiovascular health. But some research has found that tirzepatide may be even more effective than semaglutide. The side effect profiles are similar between both drugs, but may be somewhat more likely with tirzepatide.
More and longer term research will help to further elucidate any differences in efficacy and safety between the two drugs.
Tirzepatide:
- Dual GLP-1/GIP agonist.
- Potentially more effective in weight loss and blood sugar control, due to its dual-hormone mechanism.
- Higher likelihood of side effects.
- Active ingredient in Mounjardo and Zepbound.
Semaglutide:
- GLP-1 agonist only.
- Effective for weight loss and blood sugar management.
- Side effects are generally well-tolerated.
- Active ingredient in Ozempic, Wegovy, and Rybelsus.
Wegovy vs Ozempic
Wegovy and Ozempic are both injectable drugs that contain the same active ingredient, semaglutide.
There are two primary differences between Wegovy and Ozempic. The first is that Wegovy comes in a higher dose than Ozempic. They’re also FDA approved for different uses and conditions.
Wegovy is approved for weight loss in adults who are obese or who are overweight with a weight-related health condition. Wegovy is also approved for adolescents (ages 12-18) whose BMI is in the 95th percentile or higher.
Ozempic is approved to help lower blood sugar levels for adults who have type 2 diabetes.
Dosage
Ozempic and Wegovy are both weekly injections of semaglutide, but they come with different recommended dosages and different kinds of injection pens.
Ozempic starts at a dose of 0.25 mg once per week, increasing to 0.5 mg per week if needed (if blood sugar is still not regulated), and up to a maximum dosage of 2 mg once per week.
Wegovy starts at a dose of 0.25 mg, increasing to 1.7 mg per week, and up to 2.4 mg once weekly.
Ozempic comes as a multiple-use injection pen, containing four doses of the drug. For each weekly injection, you will dial up your dose, and store the pen until your next dose (or until all four doses have been used). Wegovy comes as a prefilled injection pen containing a single dose. After you’ve used it once, you’ll discard the pen.
Cost
Wegovy typically costs more than Ozempic. If paying out of pocket, Ozempic costs around $968 per month on average, and Wegovy costs around $1349.
Insurance companies may be less likely to offer coverage for weight loss drugs (like Wegovy). Most insurance companies will offer coverage for Ozempic, if you have type 2 diabetes and have been prescribed the medication for this purpose.
Weight Loss Usage
Wegovy is FDA approved for weight loss or management in adults if one of the following applies:
- Obesity (BMI of 30 or higher)
- Overweight (BMI of 27 or higher) combined with a weight-related health condition (including high cholesterol, high blood pressure, or diabetes)
Wegovy is also approved for teens ages 12+ whose BMI is in the 95th percentile or higher for their age and sex.
Ozempic isn’t currently FDA approved for weight loss. However, Ozempic, which contains the same active ingredient as Wegovy, may also lead to weight loss. Doctors may prescribe Ozempic off-label for this purpose if they feel that it’s a suitable option for you.
Medications prescribed off-label (for purposes outside of their approved uses) are not typically covered by insurance.
Other Differences
Wegovy and Ozempic are both approved to help reduce the risk of cardiovascular events like heart attack and stroke, however, the criteria are different.
Wegovy is approved for adults who have heart disease as well as obesity or overweight, and Ozempic is approved for adults who have heart disease as well as type 2 diabetes.
Wegovy vs Mounjaro
Wegovy and Mounjaro are both medications that are injected once a week. There are a few key differences between the two. Wegovy is one brand name for semaglutide (a GLP-1 receptor agonist), and Mounjaro is one brand name for tirzepatide (a dual GLP-1/GIP receptor agonist).
Wegovy and Mounjaro also have different FDA approved uses. Wegovy is approved for weight loss for those who meet certain criteria, and Mounjaro is approved for adults with type 2 diabetes.
Mounjaro and Wegovy have both been shown to lead to significant weight loss. However, Mounjaro may be more effective for this use.
Dosage
Both Wegovy and Mounjaro are once-weekly injections that come as single-use pens.
Wegovy starts at a dose of 0.25 mg, increasing to 1.7 mg per week, and up to 2.4 mg once weekly.
Mounjaro starts at a dose of 2.5 mg, gradually increasing up to 5 mg once weekly, and gradually up to a maximum of 15 mg per week as needed.
Cost
Mounjaro costs about $1069 per month on average. Wegovy costs around $1349 per month.
Many insurance companies will not cover injectable weight loss medications like Wegovy. However, they may offer coverage if you have heart disease as well as obesity or overweight, as Wegovy has also been shown to reduce the risk of major adverse cardiovascular events (MACE).
Most insurance companies will offer some coverage for Mounjaro for the purpose of treating type 2 diabetes.
Weight Loss Usage
Both Wegovy and Mounjaro have been shown to lead to weight loss, but only Wegovy is FDA approved for this purpose.
Wegovy is approved for weight loss in the following groups:
- Adults with obesity (BMI of 30 or higher)
- Adults who are overweight (BMI of 27 or higher) combined with a weight-related health condition (including high cholesterol, high blood pressure, or diabetes)
- Adolescents ages 12+ whose BMI is in the 95th percentile or higher for their age and sex.
Practitioners may in some cases prescribe Mounjaro off-label (outside of FDA-approved usage) for weight loss.
While the two drugs haven’t been directly compared in clinical trials for weight loss specifically, reviews of available research suggest that Mounjaro may be more effective than Wegovy for weight loss. The two have also been directly compared in a clinical trial for type 2 diabetes, with Mounjaro being shown to lead to more weight loss than Wegovy. A cohort study involving adults with overweight or obesity also found that tirzepatide (including Mounjaro) led to more weight loss than semaglutide (including Wegovy).
Other Differences
Wegovy has been shown to significantly lower the risk of major adverse cardiovascular events (MACE), and it is FDA approved for this use among those who have heart disease and are also obese or overweight. If you have or are at risk for heart disease, this is a factor to consider.
However, given the similarities between Wegovy and Mounjaro, it’s likely that Mounjaro could also reduce the risk of MACE, and research is currently underway to assess this.
Wegovy vs Rybelsus
Wegovy and Rybelsus are two variations of the same drug, semaglutide, but there are a few differences between them. One of the primary differences is that Wegovy is a weekly injectable medication, while Rybelsus is a pill that is taken daily. Rybelsus is the first GLP-1 receptor agonist to be made available as an oral medication.
Rybelsus and Wegovy are also FDA approved for different uses. Wegovy is approved for weight loss and management for those who meet certain criteria, while Rybelsus is approved for adults with type 2 diabetes.
Dosage
Wegovy starts at a dose of 0.25 mg, increasing to 1.7 mg per week, and up to 2.4 mg once weekly.
Rybelsus starts at a dose of 3 mg daily, increasing gradually to 7 mg, and up to 14 mg per day after 3 months if blood sugar is still not controlled.
While it may look like the dosage is much higher with Rybelsus than with Wegovy, our bodies absorb significantly less of the drug when taken orally (as with Rybelsus) compared to when injected (as with Wegovy).
Cost
Wegovy costs about $1349 per month. Rybelsus costs around $969 per month on average.
Insurance companies typically will not cover injectable weight loss medications like Wegovy. However, they may offer coverage if you have heart disease as well as obesity or are overweight.
Most insurance companies will offer some coverage for Rybelsus for the purpose of treating type 2 diabetes, though in some cases they may need to see that other diabetes medications have been tried first.
Weight Loss Usage
Wegovy and Rybelsus have both been shown to lead to weight loss, but only Wegovy is FDA approved for this purpose.
One study found that oral semaglutide (like Rybelsus) led to similar weight loss results when compared to Wegovy.
However, this study compared a very large and currently unavailable dose of oral semaglutide to a standard and available dose of Wegovy. Results may be different if comparing standard doses. Patients should not exceed the recommended dosage of Rybelsus or any other prescription medication.
Other Differences
Wegovy has been shown to significantly lower the risk of major adverse cardiovascular events (MACE). If you have or are at risk for heart disease, this is a factor to consider.
Rybelsus has been shown to have some impact on MACE reduction, but improvements have been minimal. Research is ongoing to further assess what effect Rybelsus may have on cardiovascular health.
Wegovy vs Zepbound
Wegovy and Zepbound are both weekly injectable weight loss drugs. They work in similar ways, but there are a few key differences between them.
The active ingredients in Zepbound and Wegovy are different. Zepbound is a brand name for tirzepatide, which is a dual GIP/GLP-1 agonist (it mimics two different gut hormones that may help with weight loss).
Wegovy is a brand name for semaglutide, which is a GLP-1 agonist (it mimics one gut hormone, GLP-1, which may help with weight loss).
Both Wegovy and Zepbound have been shown to help with weight loss, but Zepbound may be the more effective of the two. Both are FDA approved to help with weight loss for those who are obese or overweight with a weight-related health condition.
Dosage
Wegovy and Zepbound are both once-weekly injectable medications. With both of these medications, you will start with a smaller dosage and then work your way up to a target dose, but the dosing schedules are a bit different.
Wegovy starts at a dose of 0.25 mg, increasing to 1.7 mg per week, and up to 2.4 mg once weekly.
Zepbound starts at a dosage of 2.5 mg for 4 weeks, increasing to 5 mg once per week. If recommended, dosage may be increased every 4 weeks to up to 10 or 15 mg weekly.
Cost
Wegovy costs about $1349 per month. Zepbound costs around $1060 per month. Insurance companies don’t always offer coverage for weight loss medications like Wegovy and Zepbound, so it’s important to check with your provider before getting started.
Weight Loss Usage
Wegovy and Zepbound are both FDA approved to help with weight loss for adults who meet the following criteria:
- Obesity (BMI of 30 or higher)
- Overweight (BMI of 27 or higher) combined with a weight-related health condition (including high cholesterol, high blood pressure, or diabetes)
Currently, Zepbound is only approved for adults, while Wegvoy is also approved for adolescents ages 12 and up whose BMI is in the 95th percentile.
Both Zepbound and Wegovy have been shown to help with weight loss in clinical trials. When comparing the research, it seems that Zepbound may be somewhat more effective than Wegovy.
At least one clinical trial is currently underway comparing Wegovy and Zepbound directly. The results of this study will help to confirm or clarify the differences in effectiveness between these two drugs.
Other Differences
In addition to its weight loss benefits, Wegovy has been shown to help with the reduction of cardiovascular disease risk. This may make it a preferable option if you have or are at risk for heart disease.
Because Zepbound works similarly, it may be found to have similar cardiovascular benefits, and researchers are currently exploring this possibility. But as of now, there is more clear evidence to support Wegovy’s use for heart health, and it is the only one of the two that is FDA approved for cardiovascular risk reduction.
Ozempic vs Mounjaro
Ozempic and Mounjaro are two different, but similar, injectable medications that are both FDA approved to help manage blood sugar for adults with type 2 diabetes.
Mounjaro is a brand name for terzepatide, a drug that mimics two different hormones (GLP-1 and GIP) that both influence blood sugar and feelings of hunger. Ozempic is a brand name for semaglutide, a drug that mimics GLP-1, but not GIP.
Research suggests that Mounjaro may be more effective than Ozempic for both weight loss and blood sugar control.
Dosage
Ozempic starts at a dose of 0.25 mg once per week, increasing to 0.5 mg per week if needed, and up to a maximum dosage of 2 mg once per week.
Mounjaro starts at a dose of 2.5 mg, increasing to 5 mg once weekly, and gradually up to a maximum of 15 mg per week if needed.
Both Ozempic and Mounjaro are once weekly injections, but Ozempic comes in a multi-use pen containing 4 doses, while Mounjaro comes in a pre-filled, single use pen.
Cost
Mounjaro costs about $1069 per month on average, and Ozempic costs around $968 per month. Most insurance companies will offer coverage for Mounjaro or Ozempic if you have a diagnosis of type 2 diabetes.
Weight Loss Usage
Neither Mounjaro nor Ozempic are currently FDA approved for weight loss, but both have been shown to help with weight loss, and the active ingredients in both drugs are approved for weight loss under different brand names (Zepbound and Wegovy, respectively).
Research has shown that Mounjaro may be more effective than Ozempic for both blood sugar control and weight loss.
Other Differences
Both Mounjaro and Ozempic may also help to reduce the risk of cardiovascular events, but only Ozempic is FDA approved for this use. This may be a factor to consider if you have heart disease, especially if you may have insurance coverage for this purpose. Since Mounjaro is not FDA approved for heart disease, insurance companies will generally not offer coverage for this use.
Ozempic vs Rybelsus
Ozempic and Rybelsus are two drugs containing the same active ingredient, semaglutide. Both Rybelsus and Ozempic are FDA approved to help manage blood sugar levels for adults with type 2 diabetes.
The major difference between these two medications is that Ozempic is an injection, while Rybelsus comes as an oral tablet.
Dosage
Ozempic is an injectable drug that starts at a dose of 0.25 mg once per week, increasing to 0.5 mg per week if needed, and up to a maximum dosage of 2 mg once per week.
Rybelsus is an oral tablet. Dosage typically starts at 3 mg daily, increasing to 7 mg daily, and gradually to up to 14 mg per day after 3 months, if blood sugar levels are still not controlled.
While it may look like the dosage is much higher with Rybelsus than with Ozempic, our bodies absorb significantly less of the drug when taken orally (as with Rybelsus) compared to when injected (as with Ozempic).
Cost
Ozempic costs around $968 per month on average, and Rybelsus costs around $969 per month. Most insurance companies will offer coverage for Ozempic or Rybelsus if you have a diagnosis of type 2 diabetes. Insurance providers may need more information before approving Rybelsus (for example, to see that other blood sugar management treatments have been attempted, as Rybelsus is usually not the first recommended treatment).
Weight Loss Usage
Neither Ozempic nor Rybelsus have been FDA approved for weight loss, but another brand of semaglutide (Wegovy) has.
Ozempic and Rybelsus have both been demonstrated in research to help with weight loss. In some cases, practitioners may prescribe one of these two medications off-label for weight loss.
Other Differences
While both have been shown to help with blood sugar management for people with diabetes, and both are FDA approved for this use, Ozempic is also FDA approved to help reduce the risk of cardiovascular disease for those with diabetes. Rybelsus is not currently approved for this use.
Ozempic vs Zepbound
Ozempic and Zepbound are both weekly injectable medications. These drugs work in similar ways, but there are a few important differences between them.
Zepbound is a brand of the medication tirzepatide, and it is FDA approved for weight loss for adults who are obese or who are overweight with a weight-related health condition.
Ozempic is a brand of the medication semaglutide, and it is FDA approved to help manage blood sugar for adults with type 2 diabetes, and to lower the risk of cardiovascular events for adults with type 2 diabetes and heart disease.
Dosage
Ozempic generally starts at a dose of 0.25 mg once per week, increasing to 0.5 mg per week if needed, and up to a maximum dosage of 2 mg once per week.
Zepbound typically starts at a dosage of 2.5 mg for 4 weeks, increasing to 5 mg once per week, and gradually up to 10 or 15 mg weekly.
Both Ozempic and Zepbound are once weekly injections, but Ozempic comes in a multi-use pen that contains 4 doses, and Zepbound comes in a pre-filled, single use pen.
Cost
The average monthly cost of Ozempic is $968, and the average monthly cost of Zepbound is $1060.
Insurance providers don’t always provide coverage for injectable weight loss drugs like Zepbound. Most insurance companies will provide some coverage for Ozempic if being prescribed for type 2 diabetes.
Weight Loss Usage
Zepbound is FDA approved to help with weight loss for those who meet certain criteria. Ozempic is not currently approved for weight loss, however, research has shown that it does help people lose weight.
Zepbound may be more effective than Ozempic when it comes to weight loss.
Other Differences
In addition to blood sugar control, Ozempic has been approved to help reduce risk of major adverse cardiovascular events (MACE) for those who have type 2 diabetes and heart disease. While Zepbound may also have heart health benefits, it is not currently approved for this use.
Mounjaro vs Rybelsus
Mounjaro and Rybelsus are two medications that both mimic intestinal hormones involved in blood sugar management and weight and appetite control. Both are FDA approved to help treat type 2 diabetes.
Mounjaro is a brand of tirzepatide (a dual GLP-1/GIP receptor agonist), while Rybelsus is a brand of semaglutide (a GLP-1 receptor agonist).
The other key difference between Mounjaro and Rybelsus is that Mounjaro is an injectable medication, while Rybelsus is an oral pill.
Dosage
Rybelsus is an oral tablet. Dosage typically starts at 3 mg daily, increasing to 7 mg daily, and gradually to up to 14 mg per day after 3 months (if blood sugar levels are not controlled at 7 mg).
Mounjaro is an injectable medication which usually starts at a dose of 2.5 mg, increasing to 5 mg, and gradually up to 15 mg once per week.
Cost
Rybelsus costs around $969 per month, and Mounjaro costs about $1069 per month on average.
Most insurance companies will offer coverage for Mounjaro or Rybelsus if you have a diagnosis of type 2 diabetes. In the case of Rybelsus, some companies will require more information for approval (for example, they may want to see that you have tried other medications to help control blood sugar).
Weight Loss Usage
Neither Rybelsus nor Mounjaro is FDA approved for weight loss. However, both have been shown to help people lose weight. Some practitioners may prescribe one of these medications off-label for weight loss.
Mounjaro may be more effective than Rybelsus for weight loss, however, they haven’t been compared directly.
Mounjaro vs Zepbound
Mounjaro and Zepbound are both injectable drugs that contain the same active ingredient, tirzepatide.
The main difference between Mounjaro and Zepbound is that they have different FDA approved uses.
Zepbound is approved for weight loss in adults who are obese or who are overweight with a weight-related health condition.
Mounjaro is approved to help lower blood sugar levels for adults who have type 2 diabetes.
Dosage
The recommended dosages of Mounjaro and Zepbound are similar. Both start at a dose of 2.5 mg once per week, and gradually increase from there, up to a maximum dose of 15 mg per week.
Cost
There’s only a small cost difference between Mounjaro and Zepbound. Mounjaro usually costs around $1069 per month, and Zepbound is about $1060.
However, insurance coverage may be different. Most providers will offer coverage for Mounjaro for those who have type 2 diabetes. Insurance companies don’t tend to cover injectable weight loss drugs like Zepbound.
Weight Loss Usage
Zepbound is FDA approved for weight loss or management in adults if one of the following applies:
- Obesity (BMI of 30 or higher)
- Overweight (BMI of 27 or higher) combined with a weight-related health condition (including high cholesterol, high blood pressure, or diabetes)
Mounjaro isn’t currently FDA approved for weight loss. However, it contains the same active ingredient as Zepbound, and has also been shown to lead to weight loss. Doctors may in some cases prescribe Mounjaro off-label for weight management.
Rybelsus vs Zepbound
Rybelsus and Zepbound are two medications that both mimic hormones involved in blood sugar management and weight control. However, there are a few key differences between the two.
Zepbound and Rybelsus contain different active ingredients. Zepbound contains the dual GLP-1/GIP receptor agonist tirzepatide, and Rybelsus contains the GLP-1 receptor agonist semaglutide.
Rybelsus is FDA approved to help treat type 2 diabetes, while Zepbound is FDA approved to help manage weight for those who have obesity or who are overweight with a weight-related health condition.
Dosage
Zepbound is a weekly injection that typically starts at a dosage of 2.5 mg for 4 weeks, increasing to 5 mg once per week, and gradually up to 10 or 15 mg weekly.
Rybelsus is an oral tablet that is taken daily. Dosage usually starts at 3 mg daily, and increases gradually to 7 mg daily and up to 14 mg per day after 3 months if blood sugar levels are still not adequately controlled.
Cost
The costs of Rybelsus and Zepbound are similar. Rybelsus costs around $969 per month on average, and Zepbound is about $1060.
Insurance coverage may vary. Providers don’t tend to coverage weight loss drugs like Zepbound. They may be more likely to offer coverage for Rybelsus, if you have type 2 diabetes, and in some cases if you have also shown that other medications have not been effective at controlling your blood sugar levels.
Weight Loss Usage
Zepbound is FDA approved to help with weight loss for those who have obesity or who are overweight and have at least one weight-related health condition.
Rybelsus is not FDA approved for weight loss, but has been shown to help people lose weight. However, Zepbound may be more effective, as tirzepatide may be overall more effective than semaglutide.
What Are The Side Effects of These Weight Loss Medications?
The side effects of different injectable weight loss medications are similar, with the most common being gastrointestinal (such as nausea, stomach pain, indigestion, or constipation). However, there are a few differences. Here’s an overview of possible mild and serious side effects of each:
Ozempic Side Effects
Possible mild side effects of Ozempic may include:
- Nausea
- Stomach pain
- Constipation
- Diarrhea
- Vomiting
- Injection site reactions
More serious side effects may include severe allergic reactions, hypoglycemia, thyroid tumors, pancreatitis, kidney problems, gallbladder issues, and diabetic retinopathy.
Wegovy Side Effects
Possible mild side effects of Wegovy may include:
- Nausea
- Stomach pain
- Constipation
- Diarrhea
- Vomiting
- Dizziness
- Indigestion
- Headaches
- Fatigue
- Acid reflux
- Injection site reactions
More serious side effects may include severe allergic reactions, hypoglycemia, thyroid tumors, pancreatitis, kidney problems, gallbladder issues, tachycardia (increased heart rate), and diabetic retinopathy.
Mounjaro Side Effects
Possible mild side effects of Mounjaro may include:
- Nausea
- Diarrhea
- Vomiting
- Indigestion
- Constipation
- Burping or gas
- Stomach or abdominal pain
- Bloating
- Injection site reactions
- Mild allergic reactions
More serious side effects may include thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, increased heart rate, severe vomiting or diarrhea, and gallstones.
Zepbound Side Effects
Possible mild side effects of Zepbound may include:
- Nausea
- Stomach pain
- Constipation
- Diarrhea
- Vomiting
- Indigestion
- Fatigue
- Acid reflux
- Injection site reactions
- Hair loss
- Burping
More serious side effects may include thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, hypoglycemia, suicidal thoughts or actions, and gallstones.
Rybelsus Side Effects
Possible mild side effects of Rybelsus may include:
- Nausea
- Stomach pain
- Constipation
- Diarrhea
- Vomiting
- Decreased appetite
More serious side effects may include thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, hypoglycemia (low blood sugar), and gallstones.
| Medication | Mild Side Effects | Serious Side Effects |
|---|---|---|
| Ozempic | Nausea, stomach pain, constipation, diarrhea, vomiting, injection site reactions | Severe allergic reactions, hypoglycemia, thyroid tumors, pancreatitis, kidney problems, gallbladder issues, diabetic retinopathy |
| Wegovy | Nausea, stomach pain, constipation, diarrhea, vomiting, injection site reactions, dizziness, indigestion, headaches, fatigue, acid reflux | Severe allergic reactions, hypoglycemia, thyroid tumors, pancreatitis, kidney problems, gallbladder issues, tachycardia, diabetic retinopathy |
| Mounjaro | Nausea, diarrhea, vomiting, indigestion, constipation, injection site reactions, burping or gas, stomach pain, bloating, mild allergic reactions | Thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, increased heart rate, severe vomiting or diarrhea, gallstones |
| Zepbound | Nausea, stomach pain, constipation, diarrhea, vomiting, indigestion, fatigue, acid reflux, injection site reactions, hair loss, burping | Thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, hypoglycemia, suicidal thoughts or actions, gallstones |
| Rybelsus | Nausea, stomach pain, constipation, diarrhea, vomiting, decreased appetite | Thyroid cancer, pancreatitis, kidney failure, severe allergic reactions, vision problems, hypoglycemia, gallstones |
Reach Your Weight Loss Goals With Semaglutide
Semaglutide (the same ingredient in Wegovy and Ozempic) is recognized for its success in helping people achieve sustainable weight loss. Medical weight loss medications can help you on your journey toward your ideal weight.
Book a convenient online consultation and health check followed by a lab test. Eligible individuals will receive a medical weight loss prescription with medications delivered directly to your home.
ORDER NOW
- Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591-601. doi:10.1016/j.cmet.2016.02.005
- Brown JD, Buscemi J, Milsom V, Malcolm R, O’Neil PM. Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med. 2016;6(3):339-346. doi:10.1007/s13142-015-0353-9
- Kraftson A, Griauzde D. What Should I Know About Injectable Weight-Loss Medications? JAMA Intern Med. 2024;184(7):854. doi:10.1001/jamainternmed.2023.7268
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
- Gupta K, Raja A. Physiology, Gastric Inhibitory Peptide. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546653/
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
- Zaffina I, Pelle MC, Armentaro G, et al. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol (Lausanne). 2023;14:1095753. Published 2023 Feb 22. doi:10.3389/fendo.2023.1095753
- Farzam K, Patel P. Tirzepatide. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/
- Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
- Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab. 2020;31(6):410-421. doi:10.1016/j.tem.2020.02.006
- Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. doi:10.1001/jamainternmed.2024.2525
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
- Wojtara M, Mazumder A, Syeda Y, Mozgała N. Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. Adv Med. 2023;2023:9946924. Published 2023 Sep 20. doi:10.1155/2023/9946924
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551
- Highlights of prescribing information – Ozempic – accessdata.fda.gov. (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf
- Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. doi:10.1136/jim-2021-001952
- Highlights of prescribing information – Wegovy – accessdata.fda.gov (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- Klein, H. (n.d.). Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden. AJMC. https://www.ajmc.com/view/rising-costs-lead-insurers-to-drop-weight-loss-drug-coverage-further-increasing-patient-burden
- Will my insurance cover ozempic?. Drugs.com. (n.d.). https://www.drugs.com/medical-answers/insurance-cover-ozempic-3575100/
- Commissioner, O. of the. (n.d.). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Nordisk, N. (2020, January 16). FDA approves Ozempic® for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus® label. PR Newswire: press release distribution, targeting, monitoring and marketing. https://www.prnewswire.com/news-releases/fda-approves-ozempic-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-and-known-heart-disease-updates-rybelsus-label-300988672.html
- Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543. doi:10.1111/obr.13543
- Highlights of prescribing information – Mounjaro – accessdata.fda.gov (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866Orig1s002s006lbl.pdf
- Jung HN, Jung CH. The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. J Obes Metab Syndr. 2022;31(1):28-36. doi:10.7570/jomes22012
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11. doi:10.1016/j.ahj.2023.09.007
- Hughes S, Neumiller JJ. Oral Semaglutide. Clin Diabetes. 2020;38(1):109-111. doi:10.2337/cd19-0079
- Commissioner, O. of the. (n.d.-a). FDA approves first oral GLP-1 treatment for type 2 diabetes. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
- Andersen A, Knop FK, Vilsbøll T. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs. 2021;81(9):1003-1030. doi:10.1007/s40265-021-01499-w
- Highlights of prescribing information – Rybelsus – accessdata.fda.gov (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. doi:10.2337/dc19-0749
- Harris E. Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says. JAMA. 2023;329(23):2011. doi:10.1001/jama.2023.9601
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. doi:10.1056/NEJMoa1901118
- Janić M, Rizzo M, Cosentino F, et al. Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Ther. 2022;13(4):795-810. doi:10.1007/s13300-022-01226-y
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
- Highlights of prescribing information – Zepbound – accessdata.fda.gov (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- Commissioner, O. of the. (n.d.-c). FDA approves new medication for chronic weight management. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Clinicaltrials.gov. (n.d.). https://clinicaltrials.gov/study/NCT05822830
- Clinicaltrials.gov. (n.d.). https://clinicaltrials.gov/study/NCT05556512
- Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Results. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544016/
- Klobučar S, Belančić A, Bukša I, Morić N, Rahelić D. Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia. Diabetology. 2024; 5(1):60-68. https://doi.org/10.3390/diabetology5010005
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2021 Jul 17;398(10296):212. doi: 10.1016/S0140-6736(21)01556-7]. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6
- Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693-704. doi:10.1016/S0140-6736(23)01127-3